Clinical Trials
168
32 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1949
Completed
85
50.6%
Not yet recruiting
32
19.1%
Recruiting
38
22.6%
Suspended
1
0.6%
Unknown
12
7.1%
No approval data available
- A phase I trial of B440, an oral Bifidobacterium-based WT1 cancer vaccine, showed tolerability and immune enhancement in 12 metastatic urothelial cancer patients, with six demonstrating WT1-specific cellular immune responses. - Three of seven patients who received pembrolizumab rechallenge after B440 treatment showed tumor shrinkage, though causality could not be established in the small, non-randomized setting. - The University of Chicago received a $1.75 million NCI R01 award to develop engineered Bifidobacterium longum as a systemic delivery vehicle for IL-2 immunotherapy targeting metastatic pancreatic ductal adenocarcinoma. - Both approaches leverage Bifidobacterium's favorable safety profile as a human commensal, with the Chicago program incorporating a self-destruction gene circuit for added safety in systemic administration.
- A Kobe University-led study reveals that low-dose aspirin or heparin treatment significantly increases live birth rates in women with recurrent pregnancy loss who test positive for specific self-targeting antibodies. - The research indicates that treatment with aspirin or heparin led to an 87% live birth rate, compared to 50% in untreated women, showcasing a substantial improvement in pregnancy outcomes. - The study also found that the treatment reduced pregnancy complications from 50% to 6% among live births, highlighting the potential of these drugs to improve maternal and fetal health. - Women with only the newly discovered antibodies who received the treatment had a 93% live birth rate with no pregnancy complications, suggesting a targeted and highly effective approach.
